Safety and efficacy of protease inhibitor based combination therapy in a single-center “real-life” cohort of 110 patients with chronic hepatitis C genotype 1 infection

BACKGROUND: The combination of boceprevir or telaprevir with peginterferon-alfa and ribavirin for the treatment of patients infected with HCV genotype 1 has led to significantly increased rates of sustained virological response (SVR) in phase III trials. There is only limited data regarding the safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Wehmeyer, Malte H, Eißing, Friederike, Jordan, Sabine, Röder, Claudia, Hennigs, Annette, Degen, Olaf, Hüfner, Anja, Hertling, Sandra, Schmiedel, Stefan, Sterneck, Martina, van Lunzen, Jan, Lohse, Ansgar W, zur Wiesch, Julian Schulze, Lüth, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102246/
https://www.ncbi.nlm.nih.gov/pubmed/24884400
http://dx.doi.org/10.1186/1471-230X-14-87

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102246/
https://www.ncbi.nlm.nih.gov/pubmed/24884400
http://dx.doi.org/10.1186/1471-230X-14-87

Ejemplares similares